New clinical trial, HIV Vacc-4x in combination with Revlimid® (Lenalidomide)

Oslo – 25.08.11 – Bionor Pharma ASA Announces Exploratory Study of its Lead Therapeutic HIV-Vaccine Candidate Vacc-4x in Combination with Leading Cancer Drug The study will determine: The target patient population for the study will be HIV-patients whose immune system have not fully recovered (defined by CD4+ (helper) T-cell count in the interval 250-400 cells …

Read more

BIOtechNOW: International AIDS Conference Unveils Four New “Next Generation” Treatments for HIV

New data presented at the 2010 International AIDS Conference showed significant momentum for the emerging fields of therapeutic vaccines, anti-immune hyperactivation, and other immune based therapies for the treatment of HIV/AIDS. New data presented by researchers at the XVIII International AIDS Conference on Thursday, July 22 showed significant momentum for the emerging field of therapeutic vaccines, anti-immune …

Read more

Successful therapeutic vaccination with Vacc-4x

Successful therapeutic vaccination of HIV patients with Vacc-4x, Bionor Pharma’s peptide-based therapeutic vaccine for HIV-1 infection Bionor Pharma announced today presentation of data from its international multicenter double-blinded placebo-controlled phase IIB study at the IAS conference in Rome. As previously communicated, a statistically significant difference in viral load set point was observed between the Vacc-4x …

Read more